Concord Biotech

Which are the latest news on Concord Biotech?

Why is Concord Biotech Ltd falling/rising?

As of 05-Sep, Concord Biotech Ltd's stock price is at 1,414.75, down 2.33% today and 4.55% over the past week, underperforming the sector. Despite strong management efficiency and being net-debt free, negative market sentiment and declining investor participation indicate ongoing weakness in the stock.

As of 05-Sep, Concord Biotech Ltd's stock price is falling, currently at 1,414.75, which reflects a decrease of 33.7 points or 2.33%. The stock has underperformed compared to the sector by 1.03% today. Over the past week, the stock has declined by 4.55%, while the benchmark Sensex has only decreased by 0.97%. Additionally, the stock's performance over the last month shows a slight decline of 0.46%, contrasting with a more significant drop of 2.44% in the Sensex.<BR><BR>Today's trading session saw the stock reach an intraday low of Rs 1408.6, marking a decrease of 2.75%. Furthermore, there has been a notable decline in investor participation, with delivery volume dropping by 92.3% compared to the 5-day average. Although the stock remains above its 50-day, 100-day, and 200-day moving averages, it is currently below its 5-day and 20-day moving averages, indicating a short-term weakness.<BR><BR>Despite these negative indicators, the company maintains a high management efficiency with a return on equity (ROE) of 17.91% and is net-debt free, which are positive factors. However, the current market sentiment and trading activity suggest that these positives are not enough to counterbalance the recent downward trend in the stock price.

Who are in the management team of Concord Biotech?

The management team of Concord Biotech includes Sudhir Jairam Vaid (Chairman & Managing Director), Ankur Vaid (Joint Managing Director & CEO), and several independent and non-executive directors, totaling 13 key members who guide the company's strategic direction and operations.

The management team of Concord Biotech includes the following key individuals:<BR><BR>1. **Sudhir Jairam Vaid** - Chairman & Managing Director<BR>2. **Ankur Vaid** - Joint Managing Director & CEO<BR>3. **Ravi Kapoor** - Non-Executive Director<BR>4. **Rajiv Agarwal** - Nominee<BR>5. **Utpal Sheth** - Nominee<BR>6. **Amit Varma** - Nominee<BR>7. **Bharti Khanna** - Independent Director<BR>8. **Anil Katyal** - Independent Director<BR>9. **Amitabh Thakore** - Independent Director<BR>10. **Arvind Agarwal** - Independent Director<BR>11. **Jayaram Easwaran** - Independent Director<BR>12. **Mandayam Chakravarthy Sriraman** - Independent Director<BR>13. **S Prakash** - Vice President & Company Secretary<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

What does Concord Biotech do?

Concord Biotech Ltd is a small-cap pharmaceutical and biotechnology company, originally founded in 1984, with recent net sales of 257 Cr and a net profit of 59 Cr as of June 2026. The company has a market cap of INR 15,302 Cr and key financial metrics include a P/E ratio of 55.00 and a dividend yield of 1.23%.

Overview: <BR>Concord Biotech Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited in 1984. The company changed its name to Concord Biotech Limited in 2001, transitioning to a Public Company. The latest quarterly results report net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 257 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 59 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 15,302 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 55.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 1.23% <BR>Debt Equity: -0.20 <BR>Return on Equity: 13.06% <BR>Price to Book: 7.71 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Concord Biotech?

Peers of Concord Biotech include OneSource Speci., Shilpa Medicare, Alivus Life, Cohance Life, Alembic Pharma, Natco Pharma, Marksans Pharma, and Jubilant Pharmo. Concord Biotech has good management risk, below-average growth, and a 1-year return of -13.77%, worse than its peers.

Peers: The peers of Concord Biotech are OneSource Speci., Shilpa Medicare, Alivus Life, Cohance Life, Alembic Pharma, Natco Pharma, Marksans Pharma, Jubilant Pharmo.<BR><BR>Quality Snapshot: Excellent management risk is observed at Alivus Life, Alembic Pharma, and Natco Pharma, while Good management risk is found at Concord Biotech, Shilpa Medicare, Marksans Pharma, and the rest. Average management risk is present at Cohance Life and Jubilant Pharmo, while Below Average management risk is noted at OneSource Speci. Growth is Excellent at OneSource Speci., Good at Shilpa Medicare, and Below Average at Concord Biotech, Alivus Life, Cohance Life, Alembic Pharma, Natco Pharma, Marksans Pharma, and Jubilant Pharmo. Capital Structure is Excellent at Alivus Life, Cohance Life, Alembic Pharma, Concord Biotech, Natco Pharma, and Marksans Pharma, while Below Average is seen at OneSource Speci. and Shilpa Medicare, and Average at Jubilant Pharmo.<BR><BR>Return Snapshot: Shilpa Medicare has the highest 1-year return at 124.50%, while Cohance Life has the lowest at -48.12%. Concord Biotech's 1-year return of -13.77% is worse than the average of its peers. Additionally, Natco Pharma and Jubilant Pharmo are among the peers with negative six-month returns.

How big is Concord Biotech?

As of 31st August, Concord Biotech Ltd has a market capitalization of 15,302.00 Cr, with recent net sales of 1,108.40 Cr and a net profit of 275.38 Cr.

As of 31st August, Concord Biotech Ltd has a market capitalization of 15,302.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 1,108.40 Cr and a Net Profit of 275.38 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, with Shareholder's Funds amounting to 2,017.06 Cr and Total Assets of 2,231.79 Cr.

Should I buy, sell or hold Concord Biotech Ltd?

Are Concord Biotech Ltd latest results good or bad?

Concord Biotech Ltd's latest results show a sequential recovery with a 17.39% increase in net sales and a 37.70% rise in net profit quarter-on-quarter. However, year-on-year comparisons reveal a concerning 24.15% decline in net sales and a 36.75% drop in net profit, alongside reduced operating margins, indicating ongoing challenges for the company.

Concord Biotech Ltd's latest results present a mixed picture. On one hand, there was a notable sequential recovery in the fourth quarter of FY26, with net sales increasing by 17.39% compared to the previous quarter, reaching ₹326.08 crores. Additionally, net profit saw a significant quarter-on-quarter increase of 37.70%, amounting to ₹88.79 crores.<BR><BR>However, when looking at year-on-year performance, the results are concerning. Net sales declined by 24.15% compared to the same quarter last year, and net profit fell by 36.75% year-on-year. This decline in profitability is compounded by a significant contraction in operating margins, which decreased to 36.35% from 44.30% in the same quarter last year, indicating increased operational pressures.<BR><BR>Overall, while there are signs of recovery on a sequential basis, the year-on-year declines and margin compression suggest that the company is facing substantial challenges in its operating environment. Investors may need to approach the stock with caution until there are clearer signs of sustained improvement in both sales and profitability.

When is the next results date for Concord Biotech Ltd?

The next results date for Concord Biotech Ltd is 31 July 2026.

The next results date for Concord Biotech Ltd is scheduled for 31 July 2026.

How has been the historical performance of Concord Biotech?

Concord Biotech has shown consistent growth over the past four years, with net sales increasing from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, and profit after tax rising from 178.57 Cr to 372.96 Cr. However, cash flow management faced challenges, with a decline in operating cash flow and a net cash outflow in the latest fiscal year.

Answer:<BR>The historical performance of Concord Biotech shows a consistent growth trajectory in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Concord Biotech's net sales have increased from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 712.93 Cr to 1,200.09 Cr during the same period. The company's total expenditure, excluding depreciation, also grew from 439.66 Cr in Mar'22 to 693.76 Cr in Mar'25, indicating increased operational costs. Operating profit (PBDIT) saw a significant rise from 296.69 Cr in Mar'22 to 550.78 Cr in Mar'25, showcasing improved profitability. Profit before tax increased from 241.16 Cr to 495.87 Cr, while profit after tax rose from 178.57 Cr to 372.96 Cr, demonstrating effective cost management and revenue generation. The earnings per share (EPS) improved from 16.72 in Mar'22 to 35.53 in Mar'25, reflecting enhanced shareholder value. On the balance sheet, total assets grew from 1,312.79 Cr to 2,034.25 Cr, and total liabilities increased from 1,312.79 Cr to 2,034.25 Cr, indicating a robust growth in the company's financial position. Cash flow from operating activities showed a slight decline from 265.00 Cr in Mar'24 to 244.00 Cr in Mar'25, while net cash outflow was recorded at -14.00 Cr in Mar'25, down from a positive inflow of 11.00 Cr in Mar'24. Overall, Concord Biotech has demonstrated strong growth in sales, profits, and asset base, although cash flow management appears to have faced some challenges in the latest fiscal year.

Is Concord Biotech technically bullish or bearish?

As of October 7, 2025, Concord Biotech's trend is mildly bearish due to bearish signals from the MACD and Bollinger Bands, despite some underlying buying pressure indicated by the On-Balance Volume.

As of 7 October 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and Bollinger Bands indicating bearish signals. The daily moving averages also reflect a bearish outlook. However, the On-Balance Volume (OBV) shows bullish strength on both weekly and monthly time frames, suggesting some underlying buying pressure. Overall, the lack of strong bullish indicators and the presence of bearish signals in multiple areas indicate a cautious stance on Concord Biotech.

Who are the top shareholders of the Concord Biotech?

The top shareholders of Concord Biotech include Sudhir Vaid, who holds 28.84%, followed by 22 mutual funds with 5.16%, 92 foreign institutional investors with 9.35%, and the Aryaman Jhunjhunwala discretionary trust at 8.03%. Individual investors own a total of 6.94% of the company.

The top shareholders of Concord Biotech include the promoters, who hold the majority of the shares. The promoter with the highest holding is Sudhir Vaid, owning 28.84% of the company. Additionally, there are 22 mutual funds that collectively hold 5.16% of the shares, while 92 foreign institutional investors (FIIs) hold 9.35%. The highest public shareholder is the Aryaman Jhunjhunwala discretionary trust, which holds 8.03%. Individual investors collectively own 6.94% of the company.

Is Concord Biotech overvalued or undervalued?

As of August 21, 2023, Concord Biotech is considered very expensive and overvalued, with high valuation ratios significantly exceeding its peers, despite a strong 38.84% return over the past year.

As of 21 August 2023, Concord Biotech's valuation grade has moved from does not qualify to very expensive. The company is currently overvalued based on its high valuation ratios, including a PE ratio of 54.06, an EV to EBITDA of 39.12, and a PEG ratio of 2.41. These figures significantly exceed those of its peers, such as Sun Pharmaceutical Industries Ltd. with a PE of 35.25 and Divi's Laboratories Ltd. with an EV to EBITDA of 57.35.<BR><BR>In comparison to its peers, Concord Biotech's financial metrics suggest it is trading at a premium, indicating a lack of justification for its current price. While the company has shown strong returns over the past year, outperforming the Sensex with a 38.84% return compared to the Sensex's 7.53%, the overall valuation still reflects an overvalued status in the current market landscape.

Has Concord Biotech declared dividend?

Yes, Concord Biotech Ltd has declared an 875% dividend, amounting to ₹8.75 per share, with an ex-date of June 21, 2024. While the 1-year total return is 33.35%, the recent 6-month return is -10.59%.

Yes, Concord Biotech Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 875%<BR>- Amount per share: 8.75<BR>- Ex-date: Jun-21-2024<BR><BR>Dividend Yield: 0.47%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -10.59%, the dividend return was 0%, resulting in a total return of -10.59%.<BR><BR>For the 1-year period, the price return was 32.75%, the dividend return was 0.60%, leading to a total return of 33.35%.<BR><BR>Over the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>For the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the 5-year period, the price return was 0% and the dividend return was also 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Concord Biotech has declared a significant dividend, the total returns over various periods show mixed performance, with a notable positive return in the 1-year period but negative returns in the recent 6-month period.